JP2009514553A5 - - Google Patents

Download PDF

Info

Publication number
JP2009514553A5
JP2009514553A5 JP2008540298A JP2008540298A JP2009514553A5 JP 2009514553 A5 JP2009514553 A5 JP 2009514553A5 JP 2008540298 A JP2008540298 A JP 2008540298A JP 2008540298 A JP2008540298 A JP 2008540298A JP 2009514553 A5 JP2009514553 A5 JP 2009514553A5
Authority
JP
Japan
Prior art keywords
seq
polynucleotide
isolated
polypeptide
annexin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008540298A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009514553A (ja
Filing date
Publication date
Priority claimed from US11/267,837 external-priority patent/US7635676B2/en
Application filed filed Critical
Publication of JP2009514553A publication Critical patent/JP2009514553A/ja
Publication of JP2009514553A5 publication Critical patent/JP2009514553A5/ja
Pending legal-status Critical Current

Links

JP2008540298A 2005-11-03 2006-10-25 修飾アネキシンタンパク質および臓器移植における該タンパク質の使用法 Pending JP2009514553A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/267,837 US7635676B2 (en) 2001-02-21 2005-11-03 Modified annexin proteins and methods for their use in organ transplantation
PCT/US2006/060227 WO2007073509A2 (en) 2005-11-03 2006-10-25 Modified annexin proteins and methods for their use in organ transplantation

Publications (2)

Publication Number Publication Date
JP2009514553A JP2009514553A (ja) 2009-04-09
JP2009514553A5 true JP2009514553A5 (cg-RX-API-DMAC7.html) 2009-08-06

Family

ID=38189136

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008540298A Pending JP2009514553A (ja) 2005-11-03 2006-10-25 修飾アネキシンタンパク質および臓器移植における該タンパク質の使用法

Country Status (6)

Country Link
US (3) US7635676B2 (cg-RX-API-DMAC7.html)
EP (1) EP1957095A4 (cg-RX-API-DMAC7.html)
JP (1) JP2009514553A (cg-RX-API-DMAC7.html)
AU (1) AU2006327095A1 (cg-RX-API-DMAC7.html)
CA (1) CA2628558A1 (cg-RX-API-DMAC7.html)
WO (1) WO2007073509A2 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090291086A1 (en) * 2001-02-21 2009-11-26 Alavita Pharmaceuticals, Inc. Compositions and Methods for Treating Cerebral Thrombosis and Global Cerebral Ischemia
US7645739B2 (en) * 2001-02-21 2010-01-12 Alavita Pharmaceuticals, Inc. Modified annexin compositions and methods of using same
US20050222030A1 (en) * 2001-02-21 2005-10-06 Anthony Allison Modified annexin proteins and methods for preventing thrombosis
JP4191189B2 (ja) * 2005-12-08 2008-12-03 康生 梅津 がん関連遺伝子活性化能を有するペプチド
JP5250548B2 (ja) 2006-06-21 2013-07-31 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント 疾患の治療のための補体ｈ因子の標的化
HRP20120797T1 (hr) 2007-12-18 2012-12-31 Athera Biotechnologies Ab Spojevi i postupci za lijeäśenje vaskularne bolesti
NZ591388A (en) * 2008-08-26 2012-06-29 Mosamedix Bv Radiolabeled annexins
US8937046B2 (en) 2008-09-22 2015-01-20 The Regents Of The University Of Colorado, A Body Corporate Modulating the alternative complement pathway
JP5871798B2 (ja) 2009-07-02 2016-03-01 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント 肝再生を刺激する方法
CN102958535A (zh) 2009-11-05 2013-03-06 亚力史剑桥公司 阵发性夜间血红蛋白尿、溶血性贫血和涉及血管内和血管外溶血的疾病状态的治疗
WO2011069090A1 (en) * 2009-12-04 2011-06-09 Alavita Pharmaceuticals, Inc. Inhibition of the activation of coagulation factor xii by ligands of phosphatidylserine
MX2012013233A (es) 2010-05-14 2013-05-20 Univ Colorado Regents Grupos que apuntan a receptor 2 de complemento (cr2) mejorados.
BR112012033119A2 (pt) 2010-06-22 2016-10-25 Univ Colorado Regents anticorpos para o fragamento c3d do componente do complemento 3.
PL2694538T3 (pl) * 2011-04-05 2017-04-28 Annexin Pharmaceuticals Ab Sposoby terapeutyczne i profilaktyczne, zastosowania i kompozycje zawierające aneksynę a5
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof
JP2015535212A (ja) 2012-08-17 2015-12-10 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト 補体活性化を検出するための組成物および方法
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
US9646345B1 (en) 2014-07-11 2017-05-09 State Farm Mutual Automobile Insurance Company Method and system for displaying an initial loss report including repair information
MX2021006930A (es) 2018-12-11 2021-11-17 Q32 Bio Inc Construcciones de proteínas de fusión para enfermedades asociadas al complemento.
WO2022204517A1 (en) * 2021-03-26 2022-09-29 Emory University Managing the acute and long-term effects of coronaviral infections and compositions related thereto

Family Cites Families (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US200A (en) * 1837-05-22 Geoege
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
DE3315000A1 (de) 1983-04-26 1984-10-31 Behringwerke Ag, 3550 Marburg Gewebeprotein pp(pfeil abwaerts)4(pfeil abwaerts), verfahren zu seiner gewinnung sowie seine verwendung
US5066788A (en) 1984-09-21 1991-11-19 Boehringer Ingelheim International Gmbh Blood coagulation inhibiting proteins, processes for preparing them and their uses
KR930007434B1 (ko) 1984-09-21 1993-08-10 베링거 잉겔하임 인터내셔날 게엠베하 혈액응고 억제 단백질 제조방법
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
CA1265446A (en) 1985-09-30 1990-02-06 Masahiro Maki Anticoagulating substance, process for preparing same and anticoagulant comprising same as an effective component
JPH08840B2 (ja) 1986-11-14 1996-01-10 興和株式会社 抗ｐｃｉモノクローナル抗体、これを用いた抗ｐｃｉの精製法及び免疫学的測定法
DE3643182A1 (de) 1986-12-18 1988-06-30 Behringwerke Ag Arzneimittel enthaltend das gewebeprotein pp4, verfahren zur herstellung von pp4 und zu seiner pasteurisierung sowie die verwendung von pp4
US4937324A (en) 1987-02-06 1990-06-26 Zymogenetics, Inc. Chromatographic purification of human proteins having anticoagulant and anti-inflammatory activity
JP2660514B2 (ja) 1987-02-20 1997-10-08 興和株式会社 抗血液凝固作用を有するポリペプチド
PT87083B (pt) 1987-03-28 1992-07-31 Boehringer Ingelheim Int Processo para a preparacao de uma proteina anticoagulante vascular, de adn que codifica para esta proteina e de composicoes farmaceuticas que a contem
US4965251A (en) 1987-04-03 1990-10-23 The Board Of Regents Of The University Of Washington Pulse treatment of hemoglobinopathies with erythropoietin
DE3737239A1 (de) 1987-11-03 1989-10-12 Behringwerke Ag Gentechnische herstellung von anticoagulatorischem protein pp4
EP0330396B1 (en) 1988-02-26 1995-06-21 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing lipocortins III, IV, V & VI
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
DE4022010A1 (de) 1989-07-15 1991-01-17 Boehringer Ingelheim Int Ein antikoagulanz enthaltendes mittel
DE4021979A1 (de) 1989-07-15 1991-01-31 Boehringer Ingelheim Int Verfahren zur reinigung von annexinen
DE3937607A1 (de) 1989-11-11 1991-05-16 Boehringer Ingelheim Int Verwendung eines antikoagulanz zur behandlung von tumorerkrankungen
DE3942081A1 (de) 1989-12-20 1991-06-27 Behringwerke Ag Mittel zur verbesserung der wiederfindung von annexinen
US5627036A (en) 1989-12-27 1997-05-06 Boehringer Ingelheim International Gmbh Use of an anticoagulant as a diagnostic agent
US5225537A (en) 1989-12-29 1993-07-06 Zymogenetics, Inc. Methods for producing hybrid phospholipid-binding proteins
EP0527940A1 (en) 1990-05-08 1993-02-24 Liposome Technology, Inc. Direct spray-dried drug/lipid powder composition
EP0555328A1 (en) 1990-11-02 1993-08-18 Genentech, Inc. Platelet aggregation inhibitors
EP0558751B1 (en) 1990-11-20 2000-02-02 Kowa Co. Ltd. Therapeutic agent for the treatment of wounds
JP2916947B2 (ja) 1990-11-28 1999-07-05 興和株式会社 Ｃｐｂ―ｉの安定化方法及び製剤組成物
US5229367A (en) 1991-01-21 1993-07-20 Sclavo S.P.A. Antiinflammatory peptide derived from human lipocortin V
US5632986A (en) 1991-05-09 1997-05-27 The University Of Washington Phospholipid-targeted thrombolytic agents
CA2086437A1 (en) 1991-05-09 1992-11-10 Jonathan Tait Phospholipid-targeted thrombolytic agents
JPH051096A (ja) 1991-06-26 1993-01-08 Kowa Co 抗血液凝固活性を持つオリゴペプチド
CA2134239C (en) 1992-06-09 2004-11-23 Donald B. Axworthy Pretargeting methods and compounds
WO1994001554A1 (en) 1992-07-08 1994-01-20 N.V. Innogenetics S.A. Polypeptides, derived from endonexin 2, having hepatitis b virus receptor activity and their use in diagnostic and pharmaceutical compositions
JP3416912B2 (ja) 1992-10-08 2003-06-16 興和株式会社 抗血液凝固活性を持つオリゴペプチド
JPH0772149A (ja) 1993-06-30 1995-03-17 Nippon Shinyaku Co Ltd 肝癌又は肝硬変の診断薬及び診断法
JPH0772147A (ja) 1993-07-02 1995-03-17 Noboru Kaneko 抗アネキシンｖ抗体並びに該抗体の製法及び利用
US5849600A (en) 1993-11-10 1998-12-15 The Mclean Hospital Corporation Diagnostic assays for Alzheimer's disease
US5968477A (en) 1994-01-24 1999-10-19 Neorx Corporation Radiolabeled annexin conjugates with hexose and a chelator
WO1995034315A1 (en) 1994-06-16 1995-12-21 Neorx Corporation Radiolabeled annexin-galactose conjugates
ES2139957T3 (es) 1994-07-23 2000-02-16 Roche Diagnostics Gmbh Metodo para la determinacion del estado pretrombotico.
DE19541284C2 (de) 1995-11-06 1998-09-24 Kalden Joachim Robert Prof Dr Verfahren zur Immunmodulation
IL124831A0 (en) 1995-12-27 1999-01-26 Genentech Inc Ob protein derivatives having prolonged half-life
DE69725882T2 (de) 1996-07-05 2004-07-29 Branton, Philip E., St. Lambert Adenovirus e4 proteine für induktion von zelltod
WO1998029442A1 (en) 1996-12-30 1998-07-09 Innogenetics N.V. ANNEXIN V-BINDING POLYPEPTIDES DERIVED FROM HBsAg AND THEIR USES
DK1007082T3 (da) 1997-01-15 2007-02-19 Phoenix Pharmacologics Inc Modificeret tumor nekrose faktor
US6358508B1 (en) 1997-06-11 2002-03-19 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor TR9
US6242570B1 (en) 1997-07-10 2001-06-05 Beth Israel Deaconess Medical Center Production and use of recombinant protein multimers with increased biological activity
US6284475B1 (en) 1997-07-11 2001-09-04 Mount Sinai School Of Medicine Of The City Of New York Assays for diagnosis of thrombophilic disease
DE19734648A1 (de) 1997-08-11 1999-02-18 Dade Behring Marburg Gmbh Verwendung von Annexinen als Lupus Antikoagulans Kontrolle oder Standard in Gerinnungstesten
US6511829B1 (en) 1997-10-09 2003-01-28 The Regents Of The University Of California GFP-annexin fusion proteins
CA2305715A1 (en) 1997-11-06 1999-05-20 Innogenetics N.V. Host derived proteins binding hcv: medical, diagnostic and purification use
CA2322843A1 (en) 1998-03-27 1999-09-30 The Board Of Trustees Of The Leland Stanford, Jr. University Hypoxia-inducible human genes, proteins, and uses thereof
US6169078B1 (en) 1998-05-12 2001-01-02 University Of Florida Materials and methods for the intracellular delivery of substances
US20040002056A1 (en) 1998-05-12 2004-01-01 Lorens James B. Methods of screening for bioactive agents using cells transformed with self-inactivating viral vectors
BR9912053A (pt) 1998-07-13 2001-04-03 Univ Texas Processos de tratamento de câncer utilizando conjugados terapêuticos que se ligam a aminofosfolipìdios
WO2000010673A1 (en) 1998-08-24 2000-03-02 Nst Neurosurvival Technologies Ltd. Apparatus and method for capturing particles with surface exposure of anionic phospholipids from biological fluids
IL125908A (en) 1998-08-24 2005-05-17 Nst Neurosurvival Technologies Peptides and pharmaceutical compositions comprising same
EP1107983A2 (en) 1998-09-01 2001-06-20 Innogenetics N.V. Benzodiazepine and benzothiazepine derivatives and hbsag peptides binding to annexins, their compositions and use
SE511839C2 (sv) 1998-09-23 1999-12-06 Peter Leksell Lagerhållare innefattande åtminstone två koaxialt efter varandra anordnade lager
US6387366B1 (en) 1998-12-31 2002-05-14 Alg Company Methods for reducing adverse side effects associated with cellular transplantation
US6323313B1 (en) 1999-06-01 2001-11-27 The University Of Washington Annexin derivative with endogenous chelation sites
US20020088015A1 (en) 1999-06-04 2002-07-04 Yang Shi Wilms' tumor wt1 binding proteins
EP1441028A3 (en) 1999-07-28 2005-01-05 Interface Biotech A/S Cell cultivation method for the preparation of chondrocytes/chondroblasts
US6645465B2 (en) 1999-08-06 2003-11-11 Michigan, University Of The Regents Annexin proteins and autoantibodies as serum markers for cancer
AU7748200A (en) 1999-09-30 2001-04-30 Varian Associates, Inc. Hypoxia-related human genes, proteins, and uses thereof
EP1283904A2 (en) 1999-11-03 2003-02-19 Oncotech, Inc. Cancer diagnosis using cell-sorting and gene-expression-profiles
US20030113330A1 (en) 1999-11-08 2003-06-19 Uhal Bruce D. Methods for treating pulmonary fibrosis
FR2809181B1 (fr) 2000-05-16 2002-10-25 Biocytex Monoreactif pour le dosage des microparticules plaquettaires
US7449308B2 (en) 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
AU2001288914A1 (en) 2000-09-08 2002-03-22 Board Of Regents, The University Of Texas System Biopanning and rapid analysis of selective interactive ligands (brasil)
US7582443B2 (en) 2000-11-28 2009-09-01 Philip Gerard Cavanaugh Method for the detection and measurement of Hapten-conjugated biological binding entities by western and dot-blot using anti-hapten antibodies
AU2002252035A1 (en) * 2001-02-21 2002-09-12 Surromed, Inc. Modified annexin proteins and methods for preventing thrombosis
US20050222030A1 (en) 2001-02-21 2005-10-06 Anthony Allison Modified annexin proteins and methods for preventing thrombosis
US20030036699A1 (en) 2001-02-21 2003-02-20 Imetrx, Inc. Methods and systems which use annexin for bioprofiling body lumen
US6843980B2 (en) 2001-04-03 2005-01-18 Theseus Imaging, Corp. Methods for using annexin for detecting cell death in vivo and treating associated conditions
WO2002087497A2 (en) 2001-04-26 2002-11-07 Board Of Regents, The University Of Texas System Therapeutic agent/ligand conjugate compositions, their methods of synthesis and use
CA2444483A1 (en) 2001-04-26 2002-11-07 Board Of Regents, The University Of Texas System Diagnostic imaging compositions, their methods of synthesis and use
EP1322957B1 (en) 2001-05-04 2009-08-12 Biosite Incorporated Diagnostic markers of acute coronary syndromes and methods of use thereof
WO2002101071A2 (en) 2001-06-07 2002-12-19 Rigel Pharmaceuticals, Inc. Cd43:modulators of mast cell degranulation
CN1343777A (zh) 2001-06-26 2002-04-10 上海动物生物技术研究中心 葡激酶与Annexin V融合基因的构建及表达
AU2002324881A1 (en) * 2001-09-05 2003-03-18 Wesleyan University Diagnostic and prognostic tests
US20030152513A1 (en) 2001-09-06 2003-08-14 Imetrix, Inc. Intravascular delivery of therapeutic and imaging agents to stressed and apoptotic cells using annexin V as a targeting vector
CN1277581C (zh) 2001-09-14 2006-10-04 浙江中奇生物药业股份有限公司 一种用蚕生产抗血栓药物的方法
DE10162434A1 (de) 2001-12-18 2003-09-25 November Ag Molekulare Medizin Expressionsvektor und Verfahren zur Herstellung eines Expressionsvektors
AU2003205186A1 (en) 2002-01-16 2003-09-02 Regents Of The University Of California Functional ligand display
US20030211548A1 (en) 2002-01-29 2003-11-13 Oncolmmunin, Inc. Visualization and quantitiation of cellular cytotoxicity using cell-permeable fluorogenic protease substrates and caspase activity indicator markers
US7713981B2 (en) 2002-02-28 2010-05-11 University Of Central Florida Method and compounds for inhibition of cell death
ES2807274T3 (es) 2002-03-20 2021-02-22 Univ Maryland Un canal catiónico no selectivo en células neurales y compuestos que bloquean el canal para su uso en el tratamiento de la inflamación del cerebro
US20040029151A1 (en) 2002-04-09 2004-02-12 Affymetrix, Inc. Molecular genetic profiling of gleason grades 3 and 4/5 prostate cancer
US20040022731A1 (en) 2002-04-26 2004-02-05 Alexei Bogdanov In vivo imaging of apoptosis
GB0209896D0 (en) 2002-04-30 2002-06-05 Molmed Spa Conjugate
CN1659180B (zh) 2002-06-06 2010-06-02 温子坚 新型的重组抗凝血蛋白
WO2004006963A1 (en) 2002-07-12 2004-01-22 Beth Israel Deaconess Medical Center Conjugated infrared fluorescent substances for detection of cell death
CN1181099C (zh) 2002-07-23 2004-12-22 中国人民解放军第二军医大学 兼抗凝溶栓双重功能的血栓靶向融合蛋白mA5UKB
US20040042959A1 (en) 2002-08-28 2004-03-04 Michael Montalto Imaging cell death in vivo using non-radionuclide contrast agents
DE10253526A1 (de) 2002-11-16 2004-06-09 Johann Wolfgang Goethe-Universität Frankfurt am Main Endothelzellen als Diagnoseinstrument bei kardiovaskulären Erkrankungen
US20040203069A1 (en) 2003-04-10 2004-10-14 Chris Reutelingsperger Method for determining and/or isolating lipid-binding compounds
EP1635764A4 (en) 2003-06-17 2009-10-21 Roger G Harrison CONJUGATE FOR THE SPECIFIC TARGETING OF ANTICANCER AGENTS ON CANCER CELLS AND PRODUCTION OF THE CONJUGATE
CA2533618A1 (en) 2003-06-25 2004-12-29 Queen's University At Kingston Methods for diagnosing, monitoring, staging and treating heart failure
WO2005014801A1 (en) 2003-08-04 2005-02-17 University Court Of The University Of Edinburgh Improvements in cell culture productivity
WO2005018436A2 (en) 2003-08-26 2005-03-03 The Trustees Of Boston University Methods for the diagnosis, prognosis and treatment of metabolic syndrome
IL157786A (en) 2003-09-07 2010-11-30 Ahava Dead Sea Lab Ltd Personalized cosmetics
US20050106105A1 (en) 2003-09-09 2005-05-19 Gabe Jeffrey D. Methods and compositions for ultrasound imaging of apoptosis
US20050084547A1 (en) 2003-09-12 2005-04-21 Phytomyco Research Corporation Natural product based apoptosis inducers
WO2005028490A1 (en) 2003-09-19 2005-03-31 Theseus Imaging Corporation Halogenated deoxy-glucose labeled targeting molecules
US7634360B2 (en) 2003-09-23 2009-12-15 Prediction Sciences, LL Cellular fibronectin as a diagnostic marker in stroke and methods of use thereof
WO2005027965A1 (en) 2003-09-24 2005-03-31 Peter Krammer Antibodies against annexins, use thereof for therapy and diagnosis. use of annexins for therapy and diagnosis.
CA2542426A1 (en) 2003-10-22 2005-05-06 Fred Hutchinson Cancer Research Center Methods, compositions and devices for inducing stasis in cells
CA2485722A1 (en) 2003-10-22 2005-04-22 Paul Lehmann Soluble transferrin receptor
US20050208151A1 (en) 2003-10-30 2005-09-22 Entelos, Inc. Treatment of rheumatoid arthritis with FLIP antagonists
JP2007512369A (ja) 2003-11-26 2007-05-17 エンテロス・インコーポレーテッド 低酸素誘導因子１αアンタゴニストを用いる慢性関節リウマチの処置
WO2005058352A2 (en) 2003-12-17 2005-06-30 Entelos, Inc. Treatment of rheumatoid arthritis with galectin-3 antagonists
US20050159357A1 (en) 2003-12-17 2005-07-21 Entelos, Inc. Treatment of rheumatoid arthritis with soluble Fas-ligand cross-linkers
WO2005065418A2 (en) 2003-12-31 2005-07-21 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy
US20060134602A1 (en) 2004-01-13 2006-06-22 Littlefield Bruce A Methods of identifying cytotoxic effects in quiescent cells
CA2555866A1 (en) 2004-02-16 2005-08-25 Proteosys Ag Diagnostic markers for cancer
WO2005087275A2 (en) 2004-03-11 2005-09-22 Board Of Regents, The University Of Texas System Metal radiolabeled pet imaging agents
CA2559167A1 (en) * 2004-03-11 2005-09-22 Alavita, Inc. Modified annexin proteins and methods for preventing thrombosis
US20060099608A1 (en) 2004-03-29 2006-05-11 Medstar Research Institute Methods of diagnosing cardiovascular disease
ES2356364T3 (es) 2004-04-15 2011-04-07 Athera Biotechnologies Ab Anexina v para prevenir la ruptura de la placa.

Similar Documents

Publication Publication Date Title
JP2016531910A5 (cg-RX-API-DMAC7.html)
Breivik et al. Remote postconditioning by humoral factors in effluent from ischemic preconditioned rat hearts is mediated via PI3K/Akt-dependent cell-survival signaling at reperfusion
JP2023041917A (ja) 幹細胞を動員するための方法および組成物
Eipel et al. Ischemic preconditioning impairs liver regeneration in extended reduced-size livers
Glorion et al. Prevention of ischemia-reperfusion lung injury during static cold preservation by supplementation of standard preservation solution with HEMO2life® in pig lung transplantation model
Yu et al. Targeting complement pathways during cold ischemia and reperfusion prevents delayed graft function
UA125382C2 (uk) Антитіла проти людського vista та їх застосування
CN103403023B (zh) 细胞凋亡抑制剂及其用途
WO1995028957A3 (en) Methods for inducing t cell tolerance to a tissue or organ graft
JP2009539380A5 (cg-RX-API-DMAC7.html)
HU228108B1 (en) Graft rejection suppressing agents
AU2021202310A1 (en) Compositions and methods for treating acute radiation syndrome
TUso et al. Removal of natural human xenoantibodies to pig vascular endothelium by perfusion of blood through pig kidneys and livers
JP2005511017A (ja) ホーミングペプチド
JP2006508099A5 (cg-RX-API-DMAC7.html)
Chen et al. Co‐Delivery of G‐CSF and EPO Released From Fibrin Gel for Therapeutic Neovascularization in Rat Hindlimb Ischemia Model
RS61543B1 (sr) Postupci lečenja korišćenjem mobilizatora matične ćelije i imunosupresivnih agenasa
JP2008502592A5 (cg-RX-API-DMAC7.html)
US20150265704A1 (en) Igm therapy in prevention of onset, progression, and recurrence of autoimmune type 1 diabetes
US20260070946A1 (en) Tyr peptide compositions and methods for use
WO2004096843A1 (ja) 消化器官吸収性ポリペプチド
Broxmeyer Counteracting the enzymatic activity of dipeptidylpeptidase 4 for potential therapeutic advantage, with an emphasis on cord blood transplantation
Brunskill Albumin receptors–structure and function
Lledó-Garcia et al. Optimizing outcomes by preconditioning the donor
US20070244037A1 (en) Human Chemokine HCC-1 Polypeptides To Improve Stem Cell Transplantation